Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer

(2018) Michael B. Streiff et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

(2018) Annie M. Young et al.   JOURNAL OF CLINICAL ONCOLOGY

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis

(2018) Ang Li et al.   THROMBOSIS RESEARCH

Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease

(2017) I. Theberge et al.   THROMBOSIS RESEARCH

Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis

(2017) Jeremy A. Ross et al.   THROMBOSIS RESEARCH

Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer

(2016) S. Seo et al.   ANNALS OF ONCOLOGY

Antithrombotic Therapy for VTE Disease

(2016) Clive Kearon et al.   CHEST

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

(2016) K. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

(2016) Simon Mantha et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

(2016) Dominique Farge et al.   LANCET ONCOLOGY

The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety

(2015) Ryma Ihaddadene et al.   Expert Opinion On Drug Safety

Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology

(2015) S. Noble et al.   HAEMATOLOGICA

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer

(2015) Agnes Y. Y. Lee et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

(2015) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study

(2015) Simon Noble et al.   Patient Preference and Adherence

Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology

(2015) S. Noble et al.   HAEMATOLOGICA

Epidemiology of cancer-associated venous thrombosis

(2013) J. F. Timp et al.   BLOOD

Treatment of cancer-associated thrombosis

(2013) A. Y. Y. Lee et al.   BLOOD

Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

(2013) M. Carrier et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS